Tailoring of corticosteroids in COPD management

Area of Science:

• Pulmonology
• Pharmacology

Background:

• Updates on steroid therapy in Chronic Obstructive Pulmonary Disease (COPD) are crucial for clinical practice.
• Current guidelines and emerging evidence guide treatment strategies for both stable COPD and exacerbations.

Approach:

• Literature review of studies published within the last year.
• Critique of GOLD guidelines (2011, 2013) regarding inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) use.
• Analysis of systemic steroid courses and routes for COPD exacerbations.

Key Points:

• ICS/LABA combination therapy is preferred over LABA alone in stable COPD.
• No clear superiority among specific ICS/LABA combinations or triple therapy.
• A 5-day course of systemic steroids is favored for COPD exacerbations based on REDUCE trial findings.
• Inhaler choice and steroid type/route for exacerbations are discussed.
• Phenotyping COPD, particularly identifying steroid-responsive eosinophilic exacerbators, is a future direction.

Conclusions:

• Evidence supports ICS/LABA for stable COPD and short systemic courses for exacerbations.
• Further research into novel anti-inflammatory agents and COPD phenotyping is warranted.
• Personalized treatment approaches based on COPD phenotypes show promise.